Podcast
 |
| On this edition of The Burrill Report: Jim Greenwood, president and CEO of the Biotechnology Industry Organization, discusses the uncertainty surrounding healthcare reform, what it means for issues such as follow-on biologics, and what the industry's policy agenda looks like for 2010. |
G. Steven Burrill
Welcome from the CEO
Flash required to view this video. Download the latest version here
G. Steven BurrillNews
Biotech holds steady in January as broader markets head south February 01, 2010 | Press Release
Biotech Closes the Year on an Upswing January 04, 2010 | Press Release
Biotech gets back on track in November December 01, 2009 | Press Release
See all News
Greg B. Young
DirectorGreg B. Young joined Burrill & Company in 2000 and has been primarily involved in sourcing and evaluating new business opportunities as part of the firm's venture activities. His focus areas of investment cover renewable chemicals and energy, as well as biotechnologies enabling sustainability. Mr. Young acts as an investment manager for the Malaysian Life Sciences Capital Fund, a venture fund co-managed by Burrill & Company.
Mr. Young currently serves on the Board of HCL Cleantech and is a Board Observer on the Boards of The Brand Accelerator, Gevo and Glori Oil.
Prior to joining Burrill & Company, Mr. Young worked as a molecular biologist focused on protein expression at an early-stage biotech company located in San Diego. Mr. Young received his BS in Biochemistry and Cell Biology from the University of California, San Diego and an MS in Biotechnology and Business from Northwestern University.